Participated · Seed · Aug 2026

Nbryo develops an integrated IVF platform that combines biotechnology with digital tools to deliver scalable bovine reproductive solutions. Over the past 12 months the company commercialised its embryo multiplication technology and established a growing base of paying customers and commercial relationships with leading Australian beef producers. The business positions its offerings to improve reproductive efficiency and accelerate genetic improvement in herds. The recent A$20 million seed round, including government-backed Sowing the Seeds Fund support, is intended to fund the company's next phase of growth and further commercialisation. Nbryo has attracted investment from specialist agricultural investors and philanthropic capital, including the Gates Foundation, AgriZero, Tenacious Ventures and QIC Ventures.

Led · Equity · Mar 2026

Founded in 2021 in Perth, Rumin8 develops methane-abating feed additives for cattle by reproducing the naturally occurring compound found in red seaweed (asparagopsis) with a scalable manufacturing process. The company has shifted toward nature-inspired and derived pharmaceutical ingredients designed to reduce enteric methane while maintaining productivity and safety. Rumin8 is preparing to enter the final trial process for commercial registration of its additives and plans first commercial sales in New Zealand in 2027. It aims to decarbonise 100 million cattle by 2030 and is pursuing commercial partnerships, including a recent investment from AgriZeroNZ to support expansion into Aotearoa. Prior investors include Breakthrough Energy Ventures (Bill Gates), Harvest Road Group, Aware Super Sentient WA Growth Fund, and Prelude Ventures, following a reported $17 million seed round in 2023.

Participated · Series A · Apr 2025

Hoofprint Biome develops an enzyme feed additive that tweaks the cow rumen microbiome to suppress microbes that generate methane while increasing nutrients available to the animal. The enzymes are derived from the rumen itself and will be produced using yeast, similar to other industrial enzymes. The company targets a 5% improvement in feed efficiency (more pounds gained per unit of feed). Co-founders Kathryn Polkoff (CEO, PhD in animal science) and Scott Collins developed the approach with a farmer-facing focus on productivity and animal health. Hoofprint plans to use its latest financing to trial the enzymes on farms. The startup frames methane reduction as necessary but emphasizes that improved productivity will drive farmer adoption. Hoofprint Biome was founded by two NC State Ph.D. graduates to improve cattle gut health and reduce methane through an engineered probiotic. The company engineers Saccharomyces boulardii to deliver novel methane-preventing enzymes into the rumen while providing feed-efficiency benefits. Hoofprint is licensing NC State research-based patents and Crook’s patented delivery techniques to build its product. The startup plans to use most of its initial capital on in vivo trials and expects to double its four-person team by next year. It operates from NC State’s Plant Sciences Building on Centennial Campus and emphasizes farmer-friendly, easy-to-deploy dried-yeast feed formulations. The founders are also Breakthrough Energy Innovator Fellows and have pursued university commercialization support including the Chancellor’s Innovation Fund and a Daugherty Endowment prize.

Led · Seed · Feb 2025

Agteria Biotech is a Swedish startup founded in 2023 developing a patent-pending molecule that significantly reduces methane emissions from cattle. The company positions its solution as scalable, low-cost, and offering the highest methane reduction per euro. Agteria has demonstrated high efficacy in several in-vivo trials and has attracted interest from beef and dairy companies as well as animal feed companies. The team’s stated goal is to contribute to a 1 percent reduction in global greenhouse gas emissions by targeting enteric methane. The new €6 million seed financing will support advancement toward regulatory approval and essential safety studies for animals, consumers, and the environment. Leadership emphasizes safety, scalability, and affordability as core priorities. Agteria Biotech is developing a patent-pending enzyme-blocking feed additive aimed at reducing methane emissions from cattle. The product is based on research from the Royal Institute of Technology (KTH) and the company says it is nearly 100 times more affordable than red seaweed. Agteria is collaborating with world-class universities and regulatory authorities to validate efficacy and safety, and has secured letters of intent with several large European players. The startup is conducting in-vivo studies and working on production scaling with a target of commercial sales by 2026. Financially, Agteria recently closed a €1.4M pre-seed round led by Norrsken Launcher to advance development and commercialization efforts.

Participated · Series A · May 2024

ArkeaBio is developing a safe, user-friendly, and cost-conscious vaccine designed to reduce methane emissions from ruminant livestock and to integrate with existing global agribusiness practices. The company positions the vaccine as a scalable, low-cost tool to address agricultural methane, which the release cites as generating the equivalent of 3 billion tonnes of CO2 annually (about 6% of annual GHG emissions). ArkeaBio says its R&D results have attracted investor attention and that the vaccine is designed for rapid, on-farm implementation. The Series A proceeds will fund expansion of research and development, large-scale field trials, and engagement along the supply chain to support deployment. The company emphasizes collaborative work with industry partners, regulators, and environmental organizations to bring the product to market. Financially, ArkeaBio announced the close of a $26.5 million Series A financing to accelerate development and commercialization. ArkeaBio is a Boston, MI-based company developing an innovative vaccine to reduce methane emissions from ruminant animals, including cattle, sheep, and goats. Led by CEO Colin South, the company expects ruminant vaccinations to be a scalable and cost-effective solution to rapidly decarbonize global meat and dairy production. Its technology is intended to be integrated into proven delivery systems and existing farming practices to reduce methane emissions across multiple ruminant species, geographies, and agronomic systems. ArkeaBio intends to use newly raised funds to accelerate its research program. The company has stated it will position itself as a leader in the global effort to decarbonize the agricultural sector. No operating metrics were disclosed in the article.